Allstate Corporation’s Viking Therapeutics VKTX Stock Holding History

Allstate Corporation’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$404K	Buy	+10,345	New	+$334K	﹤0.01%	1115

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allstate Corporation's VKTX Position: Q2 2026 in Review

Allstate Corporation opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 10,345 shares worth $404K. The stake represents ﹤0.01% of the portfolio and ranks #1115 among its holdings.

433 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Allstate Corporation held 10,345 shares of Viking Therapeutics worth $404K as of Q2 2026.
Viking Therapeutics was a new Allstate Corporation position in Q2 2026.
Viking Therapeutics made up ﹤0.01% of Allstate Corporation's portfolio in Q2 2026, its #1115 holding.
433 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Allstate Corporation's 13F filing for Q2 2026, filed 13 Aug 2026.